REFERENCES
- Dawson , L. , Bateman-House , A. S. Mueller Agnew , D. 2003 . Safety issues in cell-based intervention trials . Fertility and Sterility , 80 : 1077 – 1085 .
- European Medicines Agency . 2008 . Guideline on human cell-based medicinal products . Available at: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003894.pdf (accessed January 10, 2010)
- Food and Drug Administration, Center for Biologics Evaluation and Research . 2003 . Guidance for reviewers. Instruction and template for chemistry, manufacturing, and control (CMC) reviewers of human somatic cell therapy investigational new drug applications (INDs) . Available at: http://www.fda.gov/OHRMS/DOCKETS/98fr/03d0349gdl.pdf (accessed January 10, 2010)
- Hess , P. 2012 . Intracranial stem cell-based transplantation: Reconsidering the ethics of phase 1 clinical trials in light of irreversible interventions in the brain . AJOB Neuroscience , 3 ( 2 ) : 3 – 13 .
- Preynat-Seauve , O. , Burkhardt , P. R. Villard , J. 2009 . Pluripotent stem cells as new drugs? The example of Parkinson's disease . International Journal of Pharmaceutics , 381 : 113 – 121 .
- Unger , C. , Skottman , H. , Blomberg , P. , Dilber , M. S. and Hovatta , O. 2008 . Good manufacturing practice and clinical-grade human embryonic stem cell lines . Human Molecular Genetics , 17 : R48 – R53 .